‘Small Biotech Exception’ From Medicare Price Negotiation Granted To Four Drugs For 2026
CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.
You may also be interested in...
Long-awaited list has a couple of surprises that are expected to face biosimilar competition either before negotiated prices are implemented in 2026 or during that year.
The exemption could be sought for small molecule drugs covered by Medicare Part D that have high levels of spending and are marketed by large companies, the Pharmaceutical Care Management Association suggests.
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.